Letrafem

Letrozole, the active ingredient in Letrafem, is a aromatase inhibitor presented as an oral tablet for oral use. It is employed in the endocrine treatment of hormone‑receptor positive breast cancer in postmenopausal women. GNH USA supplies Letrafem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Letrafem, an aromatase inhibitor, is indicated for conditions driven by estrogen synthesis. - Hormone receptor‑positive breast cancer (postmenopausal): Reduces estrogen‑driven tumor growth and improves disease‑free survival. - Advanced or metastatic breast cancer (postmenopausal): Delays disease progression when used as monotherapy or in combination with other agents. - Adjuvant therapy after surgery (postmenopausal): Decreases the risk of cancer recurrence in patients who have undergone tumor resection.

Letrozole may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hot flashes: Sudden feeling of warmth, often with sweating. - Arthralgia: Joint pain or stiffness. - Fatigue: Persistent tiredness not relieved by rest. - Nausea: Mild to moderate upset stomach. - Headache: Pressure or throbbing pain in the head. - Dizziness: Light‑headed sensation, especially when standing.

Serious or Rare Side Effects: - Severe liver injury: Jaundice, dark urine, elevated liver enzymes. - Bone fracture: Increased risk due to reduced bone mineral density. - Pulmonary embolism: Sudden shortness of breath, chest pain. - Anaphylaxis: Rapid onset of swelling, hives, airway compromise. - QT prolongation: Irregular heart rhythm that may lead to arrhythmia.

Before initiating Letrafem, clinicians should assess patient‑specific risk factors and monitor for potential complications. - Bone health monitoring: Perform baseline and periodic bone mineral density scans. - Liver function testing: Check hepatic enzymes prior to therapy and during treatment. - Cardiovascular assessment: Evaluate for history of thromboembolic events. - Drug interaction review: Identify concomitant medications that may alter letrozole metabolism. - Pregnancy avoidance: Ensure effective contraception; letrozole is contraindicated in pregnancy. - Store at ambient temperature (below 25°C): Keep in the original container, protect from moisture and direct sunlight.

Letrazole can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Estrogen replacement therapy: Counteracts aromatase inhibition and reduces therapeutic benefit. - Tamoxifen: Antagonistic effect on estrogen pathways, diminishing overall efficacy. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): Significantly lower plasma concentrations of letrozole.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluconazole): May increase letrozole exposure modestly. - Warfarin: Potential for enhanced anticoagulant effect; monitor INR. - Statins (especially simvastatin): Slight increase in risk of muscle toxicity; observe for myalgia.